Saira  Ramasastry net worth and biography

Saira Ramasastry Biography and Net Worth

Ms. Ramasastry is the managing partner of Life Sciences Advisory, LLC, an independent firm that she founded to provide strategic advice and business development solutions for life science companies.

Prior to founding Life Sciences Advisory, Ms. Ramasastry spent 10 years as an investment banker with Merrill Lynch & Company, where she helped establish the biotechnology practice and advised on mergers and acquisitions, and strategic and capital markets transactions.

Previously, she served as a financial analyst in mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry currently serves on the board of directors for Vir Biotechnology Inc., Mirum Pharmaceuticals Inc., Akouos, Inc., Glenmark Pharmaceuticals Ltd., and Sangamo Therapeutics, Inc., and is also a health innovator fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.

Ms. Ramasastry holds a B.A. in economics and an M.S. in management science and engineering from Stanford University, as well as an M. Phil. in management studies from the University of Cambridge.

What is Saira Ramasastry's net worth?

The estimated net worth of Saira Ramasastry is at least $337.64 thousand as of June 21st, 2024. Ms. Ramasastry owns 40,485 shares of Day One Biopharmaceuticals stock worth more than $337,645 as of December 5th. This net worth estimate does not reflect any other investments that Ms. Ramasastry may own. Learn More about Saira Ramasastry's net worth.

How do I contact Saira Ramasastry?

The corporate mailing address for Ms. Ramasastry and other Day One Biopharmaceuticals executives is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. Day One Biopharmaceuticals can also be reached via phone at 650-484-0899 and via email at [email protected]. Learn More on Saira Ramasastry's contact information.

Has Saira Ramasastry been buying or selling shares of Day One Biopharmaceuticals?

Saira Ramasastry has not been actively trading shares of Day One Biopharmaceuticals in the last ninety days. Most recently, Saira Ramasastry sold 10,000 shares of the business's stock in a transaction on Friday, June 21st. The shares were sold at an average price of $13.19, for a transaction totalling $131,900.00. Following the completion of the sale, the director now directly owns 40,485 shares of the company's stock, valued at $533,997.15. Learn More on Saira Ramasastry's trading history.

Who are Day One Biopharmaceuticals' active insiders?

Day One Biopharmaceuticals' insider roster includes Jeremy Bender (CEO), Samuel Blackman (Insider), Adam Dubow (General Counsel), Papanek Grant (Director), Lauren Merendino (Insider), Saira Ramasastry (Director), and Charles York, II (Chief Operating and Financial Officer). Learn More on Day One Biopharmaceuticals' active insiders.

Are insiders buying or selling shares of Day One Biopharmaceuticals?

During the last twelve months, insiders at the sold shares 16 times. They sold a total of 134,085 shares worth more than $1,259,570.00. The most recent insider tranaction occured on November, 17th when insider Adam Dubow sold 4,319 shares worth more than $38,482.29. Insiders at Day One Biopharmaceuticals own 6.2% of the company. Learn More about insider trades at Day One Biopharmaceuticals.

Information on this page was last updated on 11/17/2025.

Saira Ramasastry Insider Trading History at Day One Biopharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2024Sell10,000$13.19$131,900.0040,485View SEC Filing Icon  
See Full Table

Saira Ramasastry Buying and Selling Activity at Day One Biopharmaceuticals

This chart shows Saira Ramasastry's buying and selling at Day One Biopharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Day One Biopharmaceuticals Company Overview

Day One Biopharmaceuticals logo
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $8.34
Low: $8.21
High: $8.60

50 Day Range

MA: $8.08
Low: $6.77
High: $10.36

2 Week Range

Now: $8.34
Low: $5.64
High: $13.92

Volume

2,072,215 shs

Average Volume

2,762,046 shs

Market Capitalization

$856.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A